methylphenidate has been researched along with Sleep Wake Disorders in 74 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
Sleep Wake Disorders: Abnormal sleep-wake schedule or pattern associated with the CIRCADIAN RHYTHM which affect the length, timing, and/or rigidity of the sleep-wake cycle relative to the day-night cycle.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This research evaluates the preventive effects of cyproheptadine on sleeping and appetite disorders induced by methylphenidate in ADHD children." | 9.30 | Preventive effect of cyproheptadine on sleep and appetite disorders induced by methylphenidate: an exploratory randomised, double-blinded, placebo-controlled clinical trial. ( Elyasi, S; Kadkhoda Mezerji, F; Mohammadpour, AH; Moharreri, F, 2019) |
| " This research evaluates the preventive effects of cyproheptadine on sleeping and appetite disorders induced by methylphenidate in ADHD children." | 5.30 | Preventive effect of cyproheptadine on sleep and appetite disorders induced by methylphenidate: an exploratory randomised, double-blinded, placebo-controlled clinical trial. ( Elyasi, S; Kadkhoda Mezerji, F; Mohammadpour, AH; Moharreri, F, 2019) |
| "The purpose of this manuscript is to review the evidence generated by clinical trials of pharmaceuticals in autism spectrum disorder (ASD), describe challenges in the conduct of such trials, and discuss future directions RECENT FINDINGS: Clinical trials in ASD have produced several compounds to adequately support the pharmacological treatment of associated symptom domains: attention deficit hyperactivity disorder (methylphenidate, atomoxetine, and alpha agonists), irritability/aggression (risperidone and aripiprazole), sleep (melatonin), and weight gain associated with atypical antipsychotic use (metformin)." | 4.98 | Clinical trials in autism spectrum disorder: evidence, challenges and future directions. ( Anagnostou, E, 2018) |
| "Actigraphic analysis showed a higher number of night awakenings in the epilepsy + ADHD groups; they were most prominent in the group without methylphenidate (p = 0." | 3.85 | Evaluation of sleep organization in patients with attention deficit hyperactivity disorder (ADHD) and ADHD as a comorbidity of epilepsy. ( Kalil Neto, F; Nunes, ML, 2017) |
| " We report a case with sequences of CAP followed by bruxism and catathrenia in a 10-y-old male patient with a diagnosis of attention deficit hyperactivity disorder in treatment with methylphenidate." | 3.85 | Cyclic Alternating Pattern Associated with Catathrenia and Bruxism in a 10-Year-Old Patient. ( Adrianzén-Álvarez, F; Duque, KR; Palacios-García, J; Villafuerte-Trisolini, B; Vizcarra-Escobar, D, 2017) |
| "Although the FDA recommends imipramine hydrochloride (IMI) only for temporary relief of symptoms of enuresis nocturna (EN), the drug has been applied to a number of other pediatric situations, including the Hyperkinetic Syndrome (HS), childhood depression, somnambulism and pavor nocturnus, school phobia, petit mal epilepsy, allergies, autism, encorpresis and head-banging." | 3.65 | Imipramine and children: a review and some speculations about the mechanism of drug action. ( Gualtieri, CT, 1977) |
| "Methylphenidate is a first-line treatment for ADHD; its contribution to sleep problems in adult ADHD is currently unclear." | 3.30 | Effects of methylphenidate on subjective sleep parameters in adults with ADHD: a prospective, non-randomized, non-blinded 6-week trial. ( Fagerlund, B; Glenthøj, B; Habekost, T; Jepsen, JRM; le Sommer, J; Low, AM; Vangkilde, S, 2023) |
| " Pulse, blood pressure, and the presence of treatment emergent adverse events (AEs), parent and teacher AE ratings, and vital signs were recorded in each phase." | 2.72 | Safety and tolerability of methylphenidate in preschool children with ADHD. ( Abikoff, H; Chuang, S; Davies, M; Ghuman, J; Greenhill, L; Kollins, S; McCRACKEN, J; McGOUGH, J; Posner, K; Riddle, M; Skrobala, A; Stehli, A; Swanson, J; Thorp, B; Vitiello, B; Wigal, S; Wigal, T, 2006) |
| "Sleep disturbances are a feature of attention-deficit/hyperactivity disorder (ADHD) and an adverse event (AE) of methylphenidate treatment." | 2.61 | Sleep-Associated Adverse Events During Methylphenidate Treatment of Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis. ( Cortese, S; Faraone, SV; Komolova, M; Po, MD, 2019) |
| "Comorbid psychiatric disorders should be addressed with disorder-specific therapies while associated symptoms also often improve with treatment of the ADHD core symptoms." | 2.49 | [Adult attention deficit/hyperactivity disorder, associated symptoms and comorbid psychiatric disorders: diagnosis and pharmacological treatment]. ( Alm, B; Paslakis, G; Schredl, M; Sobanski, E, 2013) |
| " While medications for ADHD are generally well-tolerated, there are common, although less severe, as well as rare but severe adverse events AEs during treatment with ADHD drugs." | 2.49 | Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. ( Banaschewski, T; Buitelaar, J; Coghill, D; Cortese, S; Danckaerts, M; Dittmann, RW; Graham, J; Holtmann, M; Sergeant, J; Taylor, E, 2013) |
| "High incidence of sleep disorders in children with ADHD may be associated with a substantial impact on their quality of life and exacerbation of ADHD symptoms." | 2.47 | Pharmacological treatment of ADHD and the short and long term effects on sleep. ( Guilleminault, C; Huang, YS; Tsai, MH, 2011) |
| "Those disorders discussed are attention deficit disorder, conduct disorders, anxiety disorders, sleep disorders, schizophrenia, autism, Tourette's syndrome, mental retardation, depressive illness, manic depressive illness, eating disorders, and enuresis." | 2.37 | Pharmacologic treatment of psychiatric and neurodevelopmental disorders in children and adolescents (Part 1). ( McDaniel, KD, 1986) |
| "Sleep problems is the most common side effect of methylphenidate (MPH) treatment in ADHD youth and carry potential to negatively impact long-term self-regulatory functioning." | 1.56 | Prediction of sleep side effects following methylphenidate treatment in ADHD youth. ( Hong, SB; Kim, BN; Kim, JW; McMakin, DL; Ryan, ND; Sharma, V; Yoo, JH; Zalesky, A, 2020) |
| "To determine the prevalence of sleep disorders in children with attention-deficit/hyperactivity disorder (ADHD) and in a control population." | 1.43 | Prevalence of sleep disorders and their relationship with core symptoms of inattention and hyperactivity in children with attention-deficit/hyperactivity disorder. ( Crespo-Eguílaz, N; Guillén-Grima, F; Sánchez-Carpintero, R; Vélez-Galarraga, R, 2016) |
| "Triazolam was effective in treating the phase delay that reappeared after chronotherapy." | 1.28 | Daily activity and persistent sleep-wake schedule disorders. ( Iwata, T; Kayukawa, Y; Ohta, T; Okada, T, 1992) |
| "The cause of this syndrome is unknown, in some cases a relationship between infectious disease or traumatic brain damage has been postulated." | 1.28 | [The Kleine-Levin syndrome]. ( Boer, F; Njiokiktjien, C; Smit, LM; Smith, F; Visscher, F, 1989) |
| "Despite the fact that 57% of the ADDH group were reported to experience restless sleep on structured parental rating forms, they did not show any sleep architecture abnormalities on polysomnographic recordings when compared with the normals at baseline other than decreased rapid eye movement (REM) activity." | 1.27 | Sleep architecture and REM sleep measures in prepubertal children with attention deficit disorder with hyperactivity. ( Davies, M; Goetz, R; Greenhill, L; Hanlon, C; Puig-Antich, J, 1983) |
| "However, his hypersomnolence could be attributed to a central dysfunction, and during a follow-up period of 3 years, was successfully treated with methylphenidate." | 1.27 | Treatment of hypersomnolence in myotonic dystrophy with a CNS stimulant. ( Boogaard, JM; van den Berg, B; van der Meché, FG, 1986) |
| "A possibly different mechanism in hypersomnia and hypersexuality is speculated." | 1.26 | The Kleine-Levine syndrome--a variant? ( Nair, NP; Yassa, R, 1978) |
| "Narcolepsy may affect as many as 200,000 Americans." | 1.26 | Narcolepsy. Diagnosis and treatment. ( Carskadon, MA; Dement, WC; Guilleminault, C; Zarcone, VP, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 30 (40.54) | 18.7374 |
| 1990's | 8 (10.81) | 18.2507 |
| 2000's | 9 (12.16) | 29.6817 |
| 2010's | 23 (31.08) | 24.3611 |
| 2020's | 4 (5.41) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, Y | 1 |
| Raymer, BK | 1 |
| Low, AM | 1 |
| Vangkilde, S | 1 |
| le Sommer, J | 1 |
| Fagerlund, B | 1 |
| Glenthøj, B | 1 |
| Jepsen, JRM | 1 |
| Habekost, T | 1 |
| Yoo, JH | 1 |
| Sharma, V | 1 |
| Kim, JW | 1 |
| McMakin, DL | 1 |
| Hong, SB | 1 |
| Zalesky, A | 1 |
| Kim, BN | 1 |
| Ryan, ND | 1 |
| Mehri, M | 1 |
| Chehrzad, MM | 1 |
| Mardani, A | 1 |
| Maleki, M | 1 |
| Dianatinasab, M | 1 |
| Kousha, M | 1 |
| Assari, S | 1 |
| Fredriksen, M | 1 |
| Golparian, N | 1 |
| Beiske, K | 1 |
| Stavem, K | 1 |
| Kalil Neto, F | 1 |
| Nunes, ML | 1 |
| Howes, OD | 1 |
| Rogdaki, M | 1 |
| Findon, JL | 1 |
| Wichers, RH | 1 |
| Charman, T | 1 |
| King, BH | 1 |
| Loth, E | 1 |
| McAlonan, GM | 1 |
| McCracken, JT | 1 |
| Parr, JR | 1 |
| Povey, C | 1 |
| Santosh, P | 1 |
| Wallace, S | 1 |
| Simonoff, E | 1 |
| Murphy, DG | 1 |
| Anagnostou, E | 1 |
| Espadas, M | 1 |
| Insa, I | 1 |
| Chamorro, M | 1 |
| Alda-Diez, JA | 1 |
| Kadkhoda Mezerji, F | 1 |
| Moharreri, F | 1 |
| Mohammadpour, AH | 1 |
| Elyasi, S | 1 |
| Chin, WC | 1 |
| Huang, YS | 2 |
| Chou, YH | 1 |
| Wang, CH | 1 |
| Chen, KT | 1 |
| Hsu, JF | 1 |
| Hsu, SC | 1 |
| Faraone, SV | 2 |
| Po, MD | 1 |
| Komolova, M | 1 |
| Cortese, S | 3 |
| Myrick, L | 1 |
| Paslakis, G | 1 |
| Schredl, M | 1 |
| Alm, B | 1 |
| Sobanski, E | 1 |
| Ganelin-Cohen, E | 1 |
| Ashkenasi, A | 2 |
| Tarver, J | 1 |
| Daley, D | 1 |
| Sayal, K | 1 |
| Denlinger, CS | 1 |
| Ligibel, JA | 1 |
| Are, M | 1 |
| Baker, KS | 1 |
| Demark-Wahnefried, W | 1 |
| Friedman, DL | 1 |
| Goldman, M | 1 |
| Jones, L | 1 |
| King, A | 1 |
| Ku, GH | 1 |
| Kvale, E | 1 |
| Langbaum, TS | 1 |
| Leonardi-Warren, K | 1 |
| McCabe, MS | 1 |
| Melisko, M | 1 |
| Montoya, JG | 1 |
| Mooney, K | 1 |
| Morgan, MA | 1 |
| Moslehi, JJ | 1 |
| O'Connor, T | 1 |
| Overholser, L | 1 |
| Paskett, ED | 1 |
| Raza, M | 1 |
| Syrjala, KL | 1 |
| Urba, SG | 1 |
| Wakabayashi, MT | 1 |
| Zee, P | 1 |
| McMillian, NR | 1 |
| Freedman-Cass, DA | 1 |
| Pozzi, M | 1 |
| Bertella, S | 1 |
| Molteni, M | 1 |
| Antoniazzi, S | 1 |
| Carnovale, C | 1 |
| Gentili, M | 1 |
| Pellegrino, P | 1 |
| Perrone, V | 1 |
| Clementi, E | 1 |
| Radice, S | 1 |
| Becker, SP | 1 |
| Froehlich, TE | 1 |
| Epstein, JN | 1 |
| Vélez-Galarraga, R | 1 |
| Guillén-Grima, F | 1 |
| Crespo-Eguílaz, N | 1 |
| Sánchez-Carpintero, R | 1 |
| Villafuerte-Trisolini, B | 1 |
| Adrianzén-Álvarez, F | 1 |
| Duque, KR | 1 |
| Palacios-García, J | 1 |
| Vizcarra-Escobar, D | 1 |
| Gau, SS | 1 |
| Chiang, HL | 1 |
| Surman, CB | 1 |
| Adamson, JJ | 1 |
| Petty, C | 1 |
| Biederman, J | 1 |
| Kenealy, DC | 1 |
| Levine, M | 1 |
| Mick, E | 1 |
| Stone, P | 1 |
| Minton, O | 1 |
| Meehan, WP | 1 |
| Tsai, MH | 1 |
| Guilleminault, C | 3 |
| Walker, WC | 1 |
| Bell, KR | 1 |
| Watanabe, TK | 1 |
| Holtmann, M | 1 |
| Banaschewski, T | 1 |
| Buitelaar, J | 1 |
| Coghill, D | 1 |
| Danckaerts, M | 1 |
| Dittmann, RW | 1 |
| Graham, J | 1 |
| Taylor, E | 1 |
| Sergeant, J | 1 |
| DALY, DD | 2 |
| YOSS, RE | 3 |
| DALY, D | 1 |
| FRANKL, VE | 1 |
| DEVIC, M | 1 |
| REVOL, M | 1 |
| MICHEL, F | 1 |
| GARDE, A | 1 |
| ROBERTS, HJ | 2 |
| CRUMP, GP | 1 |
| SOURS, JA | 1 |
| SINISI, C | 1 |
| Schwartz, G | 1 |
| Amor, LB | 1 |
| Grizenko, N | 1 |
| Lageix, P | 1 |
| Baron, C | 1 |
| Boivin, DB | 1 |
| Joober, R | 1 |
| Golan, N | 1 |
| Pillar, G | 1 |
| Lecendreux, M | 1 |
| Mouren, MC | 1 |
| Konofal, E | 1 |
| Wigal, T | 1 |
| Greenhill, L | 2 |
| Chuang, S | 1 |
| McGOUGH, J | 1 |
| Vitiello, B | 1 |
| Skrobala, A | 1 |
| Swanson, J | 1 |
| Wigal, S | 1 |
| Abikoff, H | 1 |
| Kollins, S | 1 |
| McCRACKEN, J | 1 |
| Riddle, M | 1 |
| Posner, K | 1 |
| Ghuman, J | 1 |
| Davies, M | 2 |
| Thorp, B | 1 |
| Stehli, A | 1 |
| Boonstra, AM | 1 |
| Kooij, JJ | 1 |
| Oosterlaan, J | 1 |
| Sergeant, JA | 1 |
| Buitelaar, JK | 1 |
| Van Someren, EJ | 1 |
| Puig-Antich, J | 1 |
| Goetz, R | 1 |
| Hanlon, C | 1 |
| Hagel, K | 1 |
| Lenz, H | 1 |
| Rosenthal, NE | 1 |
| van der Meché, FG | 2 |
| Bogaard, JM | 1 |
| van der Sluys, JC | 1 |
| Schimsheimer, RJ | 1 |
| Ververs, CC | 1 |
| Busch, HF | 1 |
| Miller, SC | 1 |
| Ozone, M | 1 |
| Itoh, H | 1 |
| Kittur, S | 1 |
| Hauser, P | 1 |
| Jerome, L | 1 |
| Zotter, H | 1 |
| Kerbl, R | 1 |
| Millner, M | 1 |
| Kurz, R | 1 |
| Billiard, M | 1 |
| Dement, WC | 2 |
| Chiles, JA | 1 |
| Wilkus, RJ | 1 |
| Yassa, R | 1 |
| Nair, NP | 1 |
| Gualtieri, CT | 1 |
| Conner, AE | 1 |
| White, JH | 1 |
| Edwards, EM | 1 |
| Carskadon, MA | 1 |
| Zarcone, VP | 1 |
| Comly, HH | 1 |
| Danke, F | 1 |
| Dahl, RE | 1 |
| Ohta, T | 1 |
| Iwata, T | 1 |
| Kayukawa, Y | 1 |
| Okada, T | 1 |
| Weinberg, WA | 1 |
| Brumback, RA | 1 |
| McDaniel, KD | 1 |
| Visscher, F | 1 |
| Smit, LM | 1 |
| Smith, F | 1 |
| Boer, F | 1 |
| Njiokiktjien, C | 1 |
| Manfredi, RL | 1 |
| Kales, A | 1 |
| Boogaard, JM | 1 |
| van den Berg, B | 1 |
| Haig, JR | 1 |
| Schroeder, CS | 1 |
| Schroeder, SR | 1 |
| Silver, LB | 1 |
| Green, LN | 1 |
| Cracco, RQ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sleep Patterns in Children and Adolescents With ADHD: Impact on Cognitive Functions and Quality of Life[NCT03737552] | 84 participants (Actual) | Observational | 2019-04-23 | Completed | |||
| Transcranial LED Therapy for the Treatment of Chronic Mild Traumatic Brain Injury[NCT02383472] | 53 participants (Actual) | Interventional | 2012-09-30 | Completed | |||
| Open Label Study of the Effect of Individualizing Daytrana Wear-times on Sleep in Children 6-12 Years Old With Attention Deficit Hyperactivity Disorder (ADHD)[NCT00989950] | 26 participants (Actual) | Interventional | 2009-12-31 | Completed | |||
| Therapeutic Use of Repetitive Transcranial Magnetic Stimulation (rTMS) in Pediatric Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Cohorts (ADHD): a Randomized, Sham-controlled Study.[NCT06069323] | 80 participants (Anticipated) | Interventional | 2023-06-01 | Recruiting | |||
| Methylphenidate Efficacy and Safety in ADHD Preschoolers[NCT00018863] | Phase 3 | 165 participants | Interventional | 2001-04-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This measure indicates the mean differences in Delis-Kaplan Executive Function System (D-KEF) tests between entry into the study and 3 weeks and entry into the study and 6 weeks for both the LED group and the placebo group. The mean difference is calculated by taking the mean of differences of the entry scores minus the 3 week scores and the entry scores minus the 6 week scores. D-KEFs color-word interferences, made up of color naming, word reading, and inhibition, is measured in seconds, a smaller number represents a better outcome. Participants were given 90 seconds to complete color naming and word reading and 180 seconds to complete inhibition. D-KEFs trail making test, made up of number sequencing, letter sequencing, and number-letter sequencing, is measured in seconds, a faster speed (lower number) represents a better outcome. Participants were given 150 seconds to complete number and letter sequencing and 240 seconds to complete number-letter sequencing. (NCT02383472)
Timeframe: From baseline to 3 weeks and from baseline to 6 weeks
| Intervention | Seconds (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D-KEFs Color Naming - 3 Weeks | D-KEFs Color Naming - 6 Weeks | D-KEFs Word Reading - 3 Weeks | D-KEFs Word Reading - 6 Weeks | D-KEFs Inhibition - 3 Weeks | D-KEFs Inhibition - 6 Weeks | D-KEFs Number Sequencing - 3 weeks | D-KEFs Letter Sequencing- 3 weeks | D-KEFs Number-Letter Sequencing- 3 weeks | D-KEFs Number Sequencing - 6 weeks | D-KEFs Letter Sequencing- 6 weeks | D-KEFs Number-Letter Sequencing- 6 weeks | |
| MedX Health Console Model 1100 | 3.27 | 3.76 | 0.95 | 1.71 | 7.64 | 32.62 | -24.45 | -28.41 | 8.00 | 11.33 | 6.86 | 12.95 |
| MedX Health Console Model 1100-placebo | 4.76 | 4.07 | 4.07 | 3.44 | 4.48 | 31.59 | -21.17 | -19.51 | 21.93 | 6.89 | 10.59 | 19.81 |
This measure indicates the mean differences in Delis-Kaplan Executive Function System (D-KEF) tests between entry into the study and 3 weeks and entry into the study and 6 weeks for both the LED group and the placebo group. The mean difference is calculated by taking the mean of differences of the entry scores minus the 3 week scores and the entry scores minus the 6 week scores. D-KEFs Verbal Fluency Test, made up of letter fluency and category fluency, is measured by number of responses, a larger number represents a better outcome. Participants were given 60 seconds to complete each fluency test. (NCT02383472)
Timeframe: From baseline to 3 weeks and from baseline to 6 weeks
| Intervention | Correct responses (Mean) | |||
|---|---|---|---|---|
| D-KEFs Verbal Fluency- letters 3 weeks | D-KEFs Verbal Fluency- letters 6 weeks | D-KEFs Verbal Fluency- category 3 weeks | D-KEFs Verbal Fluency- category 6 weeks | |
| MedX Health Console Model 1100 | -3.45 | -6.71 | -1.14 | -1.62 |
| MedX Health Console Model 1100-placebo | -6.10 | -9.89 | -0.03 | -2.00 |
The primary outcome is mean difference on composite scores of Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) between entry into the study and completion of treatment (visit 18, week 6) for both the LED group and the placebo group. The mean difference is calculated by taking the mean of differences of the entry scores minus the 6 week scores. There are 5 composite scores on the ImPACT test; verbal memory, visual memory, visual motor speed, reaction time, and symptom score. The ranges for these subscales are as follows: verbal memory and visual memory: 0-100, visual motor speed: 0-60, reaction time: 0-1.0, and symptom score: 0-132. A higher verbal memory, visual memory, and visual motor speed represent a better outcome, while a lower reaction time and lower symptom score represent a better outcome. (NCT02383472)
Timeframe: From baseline to 6 weeks
| Intervention | Units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Verbal Memory | Visual Memory | Visual Motor Speed | Reaction Time | Symptom Score | |
| MedX Health Console Model 1100 | -0.9 | 3.52 | -2.04 | -0.001 | 10.14 |
| MedX Health Console Model 1100-placebo | -5.78 | -7.26 | -5.15 | 0.030 | 11.44 |
"This measure indicates the mean difference in total cognitive symptom scores between entry into the study and 3 weeks and entry into the study and 6 weeks for both the LED group and the placebo group. The mean difference is calculated by taking the mean of differences of the entry scores minus the 3 week scores and the entry scores minus the 6 weeks scores. The total cognitive symptom scored is a sum of 7 symptom scores from the PCSS; feeling slowed down, feeling like in a fog, don't feel right, difficulty concentrating, difficulty remembering, fatigue or low energy, and confusion. The severity of these symptoms are scored 0-6, 0=none, 6=severe. The range for the total cognitive symptom score is 0-42, a lower score represents a better outcome." (NCT02383472)
Timeframe: From baseline to 3 weeks and from baseline to 6 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Cognitive Sx Score - 3 Weeks | Cognitive Sx Score - 6 Weeks | |
| MedX Health Console Model 1100 | 3.95 | 4.00 |
| MedX Health Console Model 1100-placebo | 1.31 | 5.00 |
This measure indicates the mean differences in total post concussion symptom score (PCSS) between entry into the study and 3 weeks and entry into the study and 6 weeks for both the LED group and the placebo group. The mean difference is calculated by taking the mean of differences of the entry scores minus the 3 week scores and the entry scores minus the 6 week scores. The PCSS is a sum of severity scores from 0-6 (0=none, 6=severe) for 22 individual symptoms, like headache, neck pain, or drowsiness. The range for the PCSS is 0-132, a lower score represents a better outcome. (NCT02383472)
Timeframe: From baseline to 3 weeks and from baseline to 6 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| PCSS Total Score - 3 Weeks | PCSS Total score - 6 Weeks | |
| MedX Health Console Model 1100 | 9.41 | 7.86 |
| MedX Health Console Model 1100-placebo | 7.03 | 14.63 |
Measure by daily subject sleep diary (NCT00989950)
Timeframe: 9 weeks
| Intervention | minutes (Mean) |
|---|---|
| 9 hr Wear | 34 |
| 10 hr Wear | 34 |
| 11 hr Wear | 32 |
| 12 hr Wear | 34 |
19 reviews available for methylphenidate and Sleep Wake Disorders
| Article | Year |
|---|---|
Sleep modulating agents.
Topics: Animals; Humans; Sleep; Sleep Aids, Pharmaceutical; Sleep Wake Disorders; Wakefulness-Promoting Agen | 2019 |
Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum D | 2018 |
Clinical trials in autism spectrum disorder: evidence, challenges and future directions.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Aggression; Antipsychotic Agents; Aripipraz | 2018 |
[Side effects of methylphenidate in children and the young].
Topics: Adolescent; Anorexia; Attention Deficit Disorder with Hyperactivity; Bone Diseases, Developmental; C | 2018 |
Sleep-Associated Adverse Events During Methylphenidate Treatment of Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Child; Controlled C | 2019 |
[Adult attention deficit/hyperactivity disorder, associated symptoms and comorbid psychiatric disorders: diagnosis and pharmacological treatment].
Topics: Adult; Anxiety; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Co | 2013 |
Disordered sleep in pediatric patients with attention deficit hyperactivity disorder: an overview.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Met | 2013 |
Attention-deficit hyperactivity disorder (ADHD): an updated review of the essential facts.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Child; Child Behavior Disorders; Child Develop | 2014 |
European Palliative Care Research collaborative pain guidelines. Central side-effects management: what is the evidence to support best practice in the management of sedation, cognitive impairment and myoclonus?
Topics: Analgesics, Opioid; Central Nervous System Stimulants; Cognition Disorders; Conscious Sedation; Drug | 2011 |
Medical therapies for concussion.
Topics: Amantadine; Analgesics, Non-Narcotic; Antiparkinson Agents; Athletic Injuries; Brain Concussion; Bra | 2011 |
Pharmacological treatment of ADHD and the short and long term effects on sleep.
Topics: Actigraphy; Adolescent; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2011 |
Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure | 2013 |
NARCOLEPSY AND OTHER DISTURBANCES IN THE SLEEP-WAKING RHYTHM: A STUDY OF 115 CASES WITH REVIEW OF THE LITERATURE.
Topics: Black People; Cataplexy; Craniocerebral Trauma; Depression; Dextroamphetamine; Encephalitis; Halluci | 1963 |
[The relationship between attention deficit hyperactivity disorder and sleep-alertness problems].
Topics: Adrenergic Uptake Inhibitors; Attention Deficit Disorder with Hyperactivity; Child; Dopamine Agents; | 2004 |
[Arousal disorders].
Topics: Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Arousal; Benzodiazepines; Central Nervous Sys | 1998 |
The pharmacologic treatment of sleep disorders.
Topics: Adolescent; Antidepressive Agents, Tricyclic; Child; Child, Preschool; Deamino Arginine Vasopressin; | 1992 |
Pharmacologic treatment of psychiatric and neurodevelopmental disorders in children and adolescents (Part 1).
Topics: Adolescent; Aggression; Antidepressive Agents; Antipsychotic Agents; Anxiety, Separation; Attention | 1986 |
Clinical neuropharmacology of sleep disorders.
Topics: Antidepressive Agents; Humans; Hypnotics and Sedatives; Methylphenidate; Sleep Wake Disorders | 1987 |
The neurologic learning disability syndrome.
Topics: Anorexia Nervosa; Anxiety; Attention; Attention Deficit Disorder with Hyperactivity; Brain Damage, C | 1971 |
7 trials available for methylphenidate and Sleep Wake Disorders
| Article | Year |
|---|---|
Effects of methylphenidate on subjective sleep parameters in adults with ADHD: a prospective, non-randomized, non-blinded 6-week trial.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Follow-Up S | 2023 |
The effect of behavioral parent training on sleep problems of school-age children with ADHD: A parallel randomized controlled trial.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2020 |
Preventive effect of cyproheptadine on sleep and appetite disorders induced by methylphenidate: an exploratory randomised, double-blinded, placebo-controlled clinical trial.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Pres | 2019 |
Effect of transdermal methylphenidate wear times on sleep in children with attention deficit hyperactivity disorder.
Topics: Administration, Cutaneous; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2011 |
Actigraphic monitoring during sleep of children with ADHD on methylphenidate and placebo.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 2004 |
Safety and tolerability of methylphenidate in preschool children with ADHD.
Topics: Anorexia; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child, P | 2006 |
Hyperactive night and day? Actigraphy studies in adult ADHD: a baseline comparison and the effect of methylphenidate.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Circadian R | 2007 |
48 other studies available for methylphenidate and Sleep Wake Disorders
| Article | Year |
|---|---|
Prediction of sleep side effects following methylphenidate treatment in ADHD youth.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female | 2020 |
Impact of methylphenidate on sleep problems in adults with ADHD: a pilot polysomnography study.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Met | 2021 |
Evaluation of sleep organization in patients with attention deficit hyperactivity disorder (ADHD) and ADHD as a comorbidity of epilepsy.
Topics: Actigraphy; Adolescent; Attention Deficit Disorder with Hyperactivity; Brazil; Central Nervous Syste | 2017 |
Subjective and objective assessments of sleep problems in children with attention deficit/hyperactivity disorder and the effects of methylphenidate treatment.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior; Child; Child, Preschool; Female | 2018 |
Recognizing and treating late-life depression.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Central Nervous System Stimulants; Depressive Disord | 2019 |
Survivorship: cognitive function, version 1.2014.
Topics: Adaptation, Psychological; Benzhydryl Compounds; Brain Neoplasms; Central Nervous System Stimulants; | 2014 |
Restless Sleep in a Hyperactive Girl: A Paradoxical Adverse Reaction to Methylphenidate.
Topics: Central Nervous System Stimulants; Child; Female; Humans; Hyperkinesis; Methylphenidate; Sleep Wake | 2015 |
Effects of Methylphenidate on Sleep Functioning in Children with Attention-Deficit/Hyperactivity Disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Hum | 2016 |
Prevalence of sleep disorders and their relationship with core symptoms of inattention and hyperactivity in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2016 |
Cyclic Alternating Pattern Associated with Catathrenia and Bruxism in a 10-Year-Old Patient.
Topics: Attention Deficit Disorder with Hyperactivity; Bruxism; Central Nervous System Stimulants; Child; El | 2017 |
Sleep problems and disorders among adolescents with persistent and subthreshold attention-deficit/hyperactivity disorders.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2009 |
Association between attention-deficit/hyperactivity disorder and sleep impairment in adulthood: evidence from a large controlled study.
Topics: Adolescent; Adult; Age of Onset; Attention Deficit Disorder with Hyperactivity; Comorbidity; Diagnos | 2009 |
Use of methylphenidate during inpatient rehabilitation after traumatic brain injury.
Topics: Administration, Oral; Appetite; Brain Injuries; Central Nervous System Stimulants; Cognition Disorde | 2012 |
The treatment of narcolepsy with methyl phenylpiperidylacetate: a preliminary report.
Topics: Health Services; Humans; Methylphenidate; Narcolepsy; Sleep Wake Disorders | 1956 |
The treatment of narcolepsy with methyl phenylpiperidylacetate: a preliminary report.
Topics: Health Services; Humans; Methylphenidate; Narcolepsy; Sleep Wake Disorders | 1956 |
The treatment of narcolepsy with methyl phenylpiperidylacetate: a preliminary report.
Topics: Health Services; Humans; Methylphenidate; Narcolepsy; Sleep Wake Disorders | 1956 |
The treatment of narcolepsy with methyl phenylpiperidylacetate: a preliminary report.
Topics: Health Services; Humans; Methylphenidate; Narcolepsy; Sleep Wake Disorders | 1956 |
Treatment of narcolepsy with ritalin.
Topics: Health Services; Humans; Methylphenidate; Narcolepsy; Sleep Wake Disorders | 1959 |
[On a new principle in the treatment of chronic sleep disorders: paradoxal medication].
Topics: Chronic Disease; Health Services; Methylphenidate; Sleep; Sleep Wake Disorders | 1960 |
[Apropos of the treatment of narcolepsy: trial use of a new psychoactive agent, R.P. 8228].
Topics: Health Services; Humans; Methylphenidate; Narcolepsy; Psychotropic Drugs; Sleep Wake Disorders | 1962 |
[Results obtained with R.P. 8228 after 2 years of use of this psychotonic].
Topics: Depression; Depressive Disorder; Health Services; Methylphenidate; Sleep Wake Disorders | 1962 |
THE SYNDROME OF NARCOLEPSY AND DIABETOGENIC (FUNCTIONAL) HYPERINSULINISM. OBSERVATIONS ON 190 PATIENTS, WITH EMPHASIS UPON ITS RELATIONSHIP TO OBESITY, DIABETES MELLITUS AND CEREBRAL DYSRHYTHMIAS.
Topics: Adolescent; Alcoholism; Arrhythmias, Cardiac; Brain; Diabetes Mellitus; Diet; Diet, Reducing; Electr | 1963 |
NARCOLEPSY. A DISCUSSION AND CASE PRESENTATION.
Topics: Amphetamine; Amphetamines; Cataplexy; Diagnosis, Differential; Genetics, Medical; Hallucinations; Hu | 1963 |
[ON THE PICKWICK SYNDROME AND ITS DISTURBANCES OF A NARCOLEPTIC TYPE].
Topics: Carbon Dioxide; Diagnosis, Differential; Diet; Diet Therapy; Diuretics; Electroencephalography; Huma | 1963 |
THE SYNDROME OF NARCOLEPSY AND DIABETOGENIC ("FUNCTIONAL") HYPERINSULINISM, WITH SPECIAL REFERENCE TO OBESITY, DIABETES, IDIOPATHIC EDEMA, CEREBRAL DYSRHYTHMIAS AND MULTIPLE SCLEROSIS (200 PATIENTS).
Topics: Alcoholism; Arrhythmias, Cardiac; Cerebrovascular Disorders; Diabetes Mellitus; Drug Therapy; Edema; | 1964 |
ADHD and insomnia.
Topics: Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2006 |
Sleep architecture and REM sleep measures in prepubertal children with attention deficit disorder with hyperactivity.
Topics: Arousal; Attention Deficit Disorder with Hyperactivity; Child; Electroencephalography; Humans; Male; | 1983 |
[Narcolepsy (morbus Gélineau) (author's transl)].
Topics: Electroencephalography; Female; Hallucinations; Humans; Imipramine; Male; Methylphenidate; Narcoleps | 1980 |
[Kleine-Levin-syndrome (author's transl)].
Topics: Adolescent; Body Water; Disorders of Excessive Somnolence; Feeding and Eating Disorders; Female; Hum | 1980 |
Syndrome triad in children and adolescents.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Circadian Rhythm; Comorbidity; Female; Humans; | 1995 |
Daytime sleep in myotonic dystrophy is not caused by sleep apnoea.
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Methylphenidate; Middle Aged; Myotonic Dystrophy; Pol | 1994 |
Methylphenidate for clozapine sedation.
Topics: Clozapine; Disorders of Excessive Somnolence; Drug Monitoring; Humans; Male; Methylphenidate; Middle | 1996 |
Improvement of sleep and behavior by methylphenidate in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Drug Administration Schedule; Hospitalization; Humans; Male; Mental Disorde | 1999 |
Can methylphenidate facilitate sleep in children with attention deficit hyperactivity disorder?
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Met | 2001 |
Methylphenidate and melatonin for sleep disorder with optic glioma.
Topics: Anticonvulsants; Child; Circadian Rhythm; Dopamine Agents; Drug Therapy, Combination; Humans; Male; | 2001 |
A menstruation-linked periodic hypersomnia. Kleine-Levin syndrome or new clinical entity?
Topics: Adolescent; Disorders of Excessive Somnolence; Electroencephalography; Estrogens, Conjugated (USP); | 1975 |
Behavioral manifestations of the Kleine-Levin syndrome.
Topics: Adolescent; Behavior; Disorders of Excessive Somnolence; Electroencephalography; Humans; Male; Menta | 1976 |
The Kleine-Levine syndrome--a variant?
Topics: Adult; Disorders of Excessive Somnolence; Feeding and Eating Disorders; Humans; Hypothalamus; Male; | 1978 |
Imipramine and children: a review and some speculations about the mechanism of drug action.
Topics: Adolescent; Age Factors; Child; Child, Preschool; Depression; Dopamine; Enuresis; Epilepsy, Absence; | 1977 |
Sleep disturbance in hyperkinetic children.
Topics: Child; Child, Preschool; Dextroamphetamine; Female; Humans; Hyperkinesis; Male; Methylphenidate; Sle | 1977 |
Practical use of psychotropic drugs in children.
Topics: Adolescent; Child; Child Behavior Disorders; Enuresis; Humans; Hyperkinesis; Imipramine; Methylpheni | 1976 |
The hyperactive young child with normal intelligence.
Topics: Child; Child Behavior Disorders; Child Rearing; Child, Preschool; Crying; Feeding Behavior; Female; | 1976 |
Narcolepsy. Diagnosis and treatment.
Topics: Adolescent; Adult; Behavior; Cataplexy; Child; Diagnosis, Differential; Female; Humans; Hypoglycemia | 1976 |
Letter: Successful treatment of night terrors.
Topics: Child; Child, Preschool; Dreams; Drug Administration Schedule; Female; Humans; Imipramine; Infant; M | 1975 |
[Methylphenidate addiction--Reversal of effect on withdrawal].
Topics: Adult; Humans; Hunger; Male; Memory Disorders; Methylphenidate; Sleep Wake Disorders; Substance With | 1975 |
Daily activity and persistent sleep-wake schedule disorders.
Topics: Adolescent; Adult; Aging; Amides; Body Temperature; Circadian Rhythm; Female; Humans; Hydroxybutyrat | 1992 |
Primary disorder of vigilance: a novel explanation of inattentiveness, daydreaming, boredom, restlessness, and sleepiness.
Topics: Arousal; Attention; Attention Deficit Disorder with Hyperactivity; Boredom; Child; Child Behavior Di | 1990 |
[The Kleine-Levin syndrome].
Topics: Adolescent; Child; Disorders of Excessive Somnolence; Humans; Hyperphagia; Male; Methylphenidate; Sl | 1989 |
Treatment of hypersomnolence in myotonic dystrophy with a CNS stimulant.
Topics: Adult; Disorders of Excessive Somnolence; Humans; Male; Methylphenidate; Myotonic Dystrophy; Respira | 1986 |
Effects of methylphenidate on hyperactive children's sleep.
Topics: Adolescent; Analysis of Variance; Child; Electroencephalography; Humans; Hyperkinesis; Male; Methylp | 1974 |
Kleine-Levin syndrome. A case with EEG evidence of periodic brain dysfunction.
Topics: Adult; Arousal; Brain; Electroencephalography; Feeding and Eating Disorders; Follow-Up Studies; Huma | 1970 |